WEBULL

Seqirus Spin-Off Pause and Plasma Push Could Be A Game Changer For CSL (ASX:CSL)

Simply Wall St · 5d ago
  • CSL has recently faced increased scrutiny after cutting its fiscal 2026 revenue growth outlook, pausing the planned Seqirus spin-off in response to weaker U.S. influenza vaccination demand, and committing A$1.50 billion over five years to expand its U.S. plasma-derived therapies manufacturing capacity.
  • These moves highlight how CSL is recalibrating between a less certain vaccines backdrop and long-term investment in plasma therapies, sharpening questions about the balance between near-term earnings visibility and longer-term growth aspirations.
  • We'll now examine how CSL's shelved Seqirus spin-off and renewed plasma investment affect the existing investment narrative and future expectations.

This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

CSL Investment Narrative Recap

To own CSL today you need to believe in the long run value of its plasma, vaccines and specialty medicines portfolio, even as the share price sits near 52 week lows. The recent guidance cut and Seqirus spin off pause have sharpened focus on near term earnings sensitivity to U.S. influenza demand, while the key risk now is that weaker vaccine volumes and slower plasma recovery keep pressure on margins and investor confidence.

The planned A$1.50 billion, five year expansion of U.S. plasma derived therapies manufacturing is the announcement that matters most here, because it reinforces plasma as CSL’s primary earnings engine at a time when vaccine trends look more fragile. For investors watching upcoming results, the interaction between this long dated capital commitment and any signs of slower plasma recovery will be critical to how the story evolves from here.

Yet behind CSL’s long term healthcare appeal, investors also need to be alert to the risk that slower plasma recovery and stubborn collection costs could...

Read the full narrative on CSL (it's free!)

CSL's narrative projects $18.1 billion revenue and $4.2 billion earnings by 2028.

Uncover how CSL's forecasts yield a A$236.57 fair value, a 39% upside to its current price.

Exploring Other Perspectives

ASX:CSL 1-Year Stock Price Chart
ASX:CSL 1-Year Stock Price Chart

Twenty members of the Simply Wall St Community currently place CSL’s fair value between A$232.45 and A$308.25, underlining how far opinions can stretch. Set against lingering uncertainty over plasma recovery and vaccine demand, you are seeing very different conclusions about what the recent guidance cut and capital plans might mean for CSL’s future performance.

Explore 20 other fair value estimates on CSL - why the stock might be worth as much as 81% more than the current price!

Build Your Own CSL Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your CSL research is our analysis highlighting 6 key rewards that could impact your investment decision.
  • Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.